These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23286841)

  • 1. Optimal treatment with boceprevir for chronic HCV infection.
    Maasoumy B; Manns MP
    Liver Int; 2013 Feb; 33 Suppl 1():14-22. PubMed ID: 23286841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP; Markova AA; Calle Serrano B; Cornberg M
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
    Ramachandran P; Fraser A; Agarwal K; Austin A; Brown A; Foster GR; Fox R; Hayes PC; Leen C; Mills PR; Mutimer DJ; Ryder SD; Dillon JF
    Aliment Pharmacol Ther; 2012 Mar; 35(6):647-62. PubMed ID: 22296568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal treatment with telaprevir for chronic HCV infection.
    Jesudian AB; Jacobson IM
    Liver Int; 2013 Feb; 33 Suppl 1():3-13. PubMed ID: 23286840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to optimize HCV therapy in genotype 1 patients with cirrhosis.
    Bourlière M; Wendt A; Fontaine H; Hézode C; Pol S; Bronowicki JP
    Liver Int; 2013 Feb; 33 Suppl 1():46-55. PubMed ID: 23286846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
    Pascale A; Serfaty L
    J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
    Foote BS; Spooner LM; Belliveau PP
    Ann Pharmacother; 2011 Sep; 45(9):1085-93. PubMed ID: 21828346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Boceprevir and treatment of chronic hepatitis C.
    Kwo PY
    Clin Liver Dis; 2013 Feb; 17(1):63-72. PubMed ID: 23177283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon free therapy with direct acting antivirals for HCV.
    Asselah T; Marcellin P
    Liver Int; 2013 Feb; 33 Suppl 1():93-104. PubMed ID: 23286852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anemia management in patients with chronic viral hepatitis C.
    Hynicka LM; Heil EL
    Ann Pharmacother; 2013 Feb; 47(2):228-36. PubMed ID: 23386076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.
    Sultanik P; Mallet V; Lagaye S; Casrouge A; Dorival C; Barthe Y; Fontaine H; Hézode C; Mottez E; Bronowicki JP; Carrat F; Theodorou I; Abel L; Gayat E; Fontanet A; Pol S; Albert ML;
    Liver Int; 2015 Jul; 35(7):1833-44. PubMed ID: 25556540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to optimize HCV therapy in genotype 2 patients.
    Grassi E; Aghemo A
    Liver Int; 2013 Feb; 33 Suppl 1():35-40. PubMed ID: 23286844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
    Marks KM; Jacobson IM
    Antivir Ther; 2012; 17(6 Pt B):1119-31. PubMed ID: 23188750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.
    Forestier N; Zeuzem S
    Liver Int; 2012 Feb; 32 Suppl 1():44-50. PubMed ID: 22212571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders.
    Bacon BR; Khalid O
    Liver Int; 2012 Feb; 32 Suppl 1():51-3. PubMed ID: 22212572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future treatment of patients with HCV cirrhosis.
    Bourlière M; Khaloun A; Wartelle-Bladou C; Oules V; Portal I; Benali S; Adhoute X; Castellani P
    Liver Int; 2012 Feb; 32 Suppl 1():113-9. PubMed ID: 22212581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Ferenci P; Reddy KR
    Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.
    Sitole M; Silva M; Spooner L; Comee MK; Malloy M
    Clin Ther; 2013 Feb; 35(2):190-7. PubMed ID: 23369368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience.
    Faisal N; Yoshida EM; Bilodeau M; Wong P; Ma M; Burak KW; Al-Judaibi B; Renner EL; Lilly LB
    Ann Hepatol; 2014; 13(5):525-32. PubMed ID: 25152985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.